




The relative strengths and weaknesses of Zevra Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zevra Therapeutics INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Zevra Therapeutics INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 75% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	223,007
Cost of Goods Sold	0
Intangible Assets	11,122
Liabilities, Current	39,277
Liabilities, Non-Current	64,500
Other Assets	50,113
Other Compr. Net Income	-1,395
Other Expenses	82,503
Other Liabilities	26,297
Other Net Income	149,621
Other Revenues	106,470
Property and Equipment	489
Research and Development	12,743
Selling, General and Administrative Expense	77,616

Output Variable	Value in 1000 USD
Assets	284,731
Liabilities	130,074
Expenses	172,862
Revenues	106,470
Stockholders Equity	154,657
Net Income	83,229
Comprehensive Net Income	82,532
BaseVar	422,576
ECR before LimitedLiability	202%
Economic Capital Ratio	304%